2015 News Releases

Webcast ImageWebcast
Zogenix, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/22/17 at 2:10 p.m. ET
Zogenix, Inc. at Oppenheimer 27th Annual Healthcare Conference
Wednesday, March 22, 2017 2:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/14/15Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome
SAN DIEGO, Dec. 14, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for Zogenix’s lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.  The active IND now allows the Company to initiate its planned P... 
Printer Friendly Version
12/07/15Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
New Clinical Data Presented at 69th Annual American Epilepsy Society Meeting on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome SAN DIEGO, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced new data demonstrating sustained effectiveness and cardiovascular-related safety for patients treated with ZX008 (low-dose fenfluramine) ... 
Printer Friendly Version
11/25/15New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting
Three Poster Presentations will Highlight Efficacy, Cardiovascular Safety and Mechanism of Action of Low-Dose Fenfluramine in the Treatment of Dravet Syndrome Zogenix will also Host a Scientific Exhibit Room: "History of the Use of Low-dose Fenfluramine in Pediatric Epilepsy" SAN DIEGO, Nov. 25, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the presentation o... 
Printer Friendly Version
11/11/15Zogenix to Participate in Stifel 2015 Healthcare Conference
SAN DIEGO, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Stifel 2015 Healthcare Conference in New York, NY, on November 18, 2015. Stifel 2015 Healthcare Conference Date: Wednesday, November 18, 2015 Time: ... 
Printer Friendly Version
11/09/15Zogenix Provides Corporate Update and Reports Third Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EST/1:30 p.m. PST SAN DIEGO, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced financial results for the third quarter ended September 30, 2015. Corporate Update Continued preparations for the Phase 3 program for ZX008, which is expected to begin in the fourth quarter ... 
Printer Friendly Version
11/02/15Zogenix to Release Third Quarter 2015 Financial Results and Host Conference Call & Webcast on November 9
SAN DIEGO, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2015 after the market close, and will host a corporate update conference call and webcast on Monday, November 9, 2015, at 4:30pm Eastern Time. Monday, November 9th @ 4:30pm Eastern Time/1:30pm Pacific T... 
Printer Friendly Version
10/19/15Zogenix Provides Regulatory Update for ZX008
Company Continues to Expect Phase 3 Clinical Program to Begin in Fourth Quarter of 2015 SAN DIEGO, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the recent receipt of a request from the U.S. Food and Drug Administration (FDA) for additional information related to the Company's proposed Phase 3 program for ZX008 prior to the FDA declaring Zogenix's Investiga... 
Printer Friendly Version
09/30/15Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial
Product Candidate Now Phase 3 Ready Company Initiates Efforts to Secure Global Development and Commercialization Partner SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced positive top-line pharmacokinetic results from its Phase 1b multi-dose clinical trial of Relday™, a proprietary, once-monthly subcutaneous investigational formulation of ris... 
Printer Friendly Version
09/23/15Zogenix to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable
SAN DIEGO, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Leerink Partners 4th Annual Rare Disease Roundtable in New York, NY, on September 30, 2015. Leerink Partners 4th Annual Rare Disease Roundtable Date: Wednesday, Septembe... 
Printer Friendly Version
09/03/15Zogenix to Participate in the Wells Fargo 2015 Healthcare Conference
SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Wells Fargo 2015 Healthcare Conference in Boston, MA, on September 10, 2015. Wells Fargo 2015 Healthcare Conference Date: Thursday, September 10, 2015 T... 
Printer Friendly Version
08/10/15Zogenix Provides Corporate Update and Reports Second Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced financial results for the second quarter ended June 30, 2015. Corporate Update Presented new data at European Paediatric Neurology Society Congress in Vienna, Austria, de... 
Printer Friendly Version
08/05/15Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of 5,462,500 shares of its common stock, including 712,500 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $18.00 per share. ... 
Printer Friendly Version
08/03/15Zogenix to Release Second Quarter 2015 Financial Results and Host Conference Call & Webcast on August 10
SAN DIEGO, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2015 after the market close, and will host a corporate update conference call and webcast on Monday, August 10, 2015 at 4:30pm Eastern Time. Monday, August 10, 2015 @ 4:30pm Eastern Time/... 
Printer Friendly Version
07/30/15Zogenix Prices Public Offering of Common Stock
SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds from the offering, before underwriting discounts and commissions and offering costs, are expected to be approximately $8... 
Printer Friendly Version
07/28/15Zogenix Announces Proposed Public Offering of 3,800,000 Shares of Common Stock
SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today that it intends to offer and sell 3,800,000 shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters for the offering a 30-day option to purchase an additional 570,000 shares of common stock offered in the public offerin... 
Printer Friendly Version
07/07/15Zogenix to Host Key Opinion Leader Meeting Tuesday, July 14, in New York City
SAN DIEGO, July 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader breakfast focused on Dravet syndrome, including an overview of ZX008, the Company's investigational proprietary pediatric formulation of low-dose fenfluramine, which is designated as an orphan drug for the treatment of Dravet syndrome in ... 
Printer Friendly Version
07/06/15Zogenix Expands Senior Leadership Team to Further Drive Strategic Focus on CNS Disorders and Orphan Drug Development
Company Appoints Dr. Gail Farfel as Chief Development Officer and Dr. Thierry Darcis as General Manager, Europe SAN DIEGO, July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today the appointments of Gail M. Farfel, Ph.D., as Executive Vice President and Chief Development Officer, and Thierry Darcis, M.D., M.B.A., as Executive Vice President and Gene... 
Printer Friendly Version
07/06/15Zogenix to Participate in Cantor Fitzgerald Healthcare Conference
SAN DIEGO, July 6, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Cantor Fitzgerald Healthcare Conference in New York, NY, on July 8, 2015. Cantor Fitzgerald Healthcare Conference Date: Wednesday, July 8, 2015 ... 
Printer Friendly Version
06/18/15Zogenix Announces Shareholders and Board of Directors Approve Reverse Stock Split
SAN DIEGO, June 18, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that at the annual general meeting of shareholders held earlier today, shareholders voted to approve a proposal authorizing the board of directors of the Company to amend the Company's certificate of incorporation to effect a reverse stock split of Zogenix's outstanding common shares... 
Printer Friendly Version
05/27/15Zogenix Announces New Efficacy Data From a Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome
New data presented at European Paediatric Neurology Society Congress in Vienna, Austria includes 10 patients who continued treatment with low-dose fenfluramine for Dravet syndrome following the original study published in 2012, plus 2 new patients who began treatment in 2011 During 5-year follow-up period from 2010-2014: At least 80% of patients experienced a greater than or equal to 75% reduction in seizure frequency every year A majority of patients experien... 
Printer Friendly Version
05/11/15Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO, May 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced financial results for the first quarter ended March 31, 2015. Corporate Update Appointed Stephen J. Farr, Ph.D., previously serving as the Company's President, as the new ... 
Printer Friendly Version
05/04/15Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2015 after the market close, and will host a corporate update conference call and webcast on Monday, May 11, 2015 at 4:30pm Eastern Time. Monday, May 11, 2015 @ 4:30pm Eastern Time/1:30pm ... 
Printer Friendly Version
04/27/15Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS Product Pipeline
SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it is implementing its succession plan as the Company focuses on advancing its late-stage product development pipeline. Zogenix's Board of Directors has unanimously appointed Stephen Farr, Ph.D., previously serving as the Company's President, as Roger Hawley's successor and new... 
Printer Friendly Version
04/24/15Zogenix Closes Sale of Zohydro(R) ER Business to Pernix
Strategic Focus Shifts to Zogenix's High Value Late-Stage CNS Pipeline SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has closed the sale of its Zohydro® ER (hydrocodone bitartrate) business to a wholly-owned subsidiary of Pernix Therapeutics Holdings, Inc. (Nasdaq:PTX) for $80 million in cash, approximately 1.68 millio... 
Printer Friendly Version
03/26/15Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study
Results Anticipated in Third Quarter 2015, Positioning Zogenix for Potential World-Wide Partnering Opportunities for Relday SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that dosing has begun in patients enrolled in its Relday™ multi-dose Phase 1b clinical study. Relday is a proprietary, long-acting, subcutaneously injected fo... 
Printer Friendly Version
03/10/15Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million
Enables planned implementation of new strategic focus to developing a late-stage, high-value CNS pipeline Conference Call and Webcast on Tuesday, March 10, at 4:30 p.m. ET Agreement Terms: $100 million in upfront consideration comprised of $30 million in cash, $20 million in Pernix common stock and a $50 million short term promissory note $12.5 million milestone payment for approval of ZX007 abuse-deterrent extended-release hydrocodone tablet (the Altus formulation) ... 
Printer Friendly Version
03/10/15Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results
Conference Call and Webcast to Discuss Fourth Quarter Results and Definitive Agreement to Sell Zohydro ER to Pernix; Scheduled for Today, March 10, at 4:30 p.m. ET Clinical and Regulatory Update Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™ On track to begin Phase 3 clinical study for ZX008 (orphan drug candidate for Dravet syndrome) in the third quarter 2015; data expected in 2016 Enrolled ... 
Printer Friendly Version
03/02/15Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2014 Financial Results
Conference Call Scheduled for March 10, 2015 at 4:30 pm ET SAN DIEGO, March 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market closes on Tuesday, March 10, 2015, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), ... 
Printer Friendly Version
02/10/15Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
SAN DIEGO, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the Company's Board of Directors. Cam L. Garner, Chairman of the Board, said, "Dr. Tannenbaum has significant experience developing and executing commercial strategies in the pharmaceutical industry. Her stron... 
Printer Friendly Version
02/05/15Zogenix to Participate in Leerink Global Healthcare Conference
SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will present at the Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Ms. Rhoads will participate in a fireside chat presentation and provide a general company update. Event: Leerink Global ... 
Printer Friendly Version
01/30/15Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
Zohydro ER With BeadTek(TM) to be Available in the Second Quarter of 2015 SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™. BeadTek is a formulation technology design... 
Printer Friendly Version
01/12/15Zogenix Provides Business Update
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights, the most recent Zohydro ER prescription trends and the Company's year-end 2014 cash position. Business Update: Acquired Brabant Pharma on October 24, 2014, obtaining global rights for an or... 
Printer Friendly Version